

February 9, 2017



ITUS to Present at UK Biotech Capital Conference

LOS ANGELES, CA -- (Marketwired) -- 02/09/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that its President & CEO, Robert Berman, will present at the Biotech Capital Conference in London, England on February 21, 2017 at 10:30 am.

Biotech Capital is the largest healthcare investor conference in the U.K., which includes asset managers, private client brokers, family offices, analysts, and wealth managers. The conference is being held at The Brewery (Chiswell Street, EC1Y 4SD).

ITUS Corporation

[ITUS](#) funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology. The Company is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such

forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

Contact:

Dean Krouch

310-484-5184

dkrouch@ITUScorp.com

Source: ITUS Corporation